Nuvita İlaç Continues Its Rise in the R&D 500

Nuvita İlaç, Orzax’s strategic production center, continued its rise in R&D performance in the Türkiye R&D 500 Research conducted by Turkishtime. The company climbed 17 places to 231st in R&D expenditures, while rising 24 places to 41st in the number of R&D projects.

The 2025 results of the Türkiye R&D 500 Research, conducted annually by the economy and business world portal Turkishtime, have been announced. In the research, which presents important indicators regarding Türkiye’s R&D ecosystem, Nuvita İlaç, which undertakes Orzax’s production activities, drew attention with the increase in its R&D investments and number of projects.

According to the research, Nuvita İlaç increased its R&D expenditures by 53.8 percent in 2025, raising them to TRY 84.8 million. With this increase, the company rose from 248th place last year to 231st place in the ranking of companies with the highest R&D expenditures in Türkiye, strengthening its position within the top 250.

Nuvita İlaç’s performance in the research was not limited to the increase in R&D investments alone. The company increased the number of R&D projects it carries out from 38 to 49, an increase of 28.9 percent.

With this result, Nuvita İlaç rose from 65th place last year to 41st place in the ranking of companies carrying out the most R&D projects. Thus, the company entered the top 50 companies carrying out the most R&D projects in Türkiye.

Nuvita İlaç continues its R&D efforts in line with its goals of developing innovative solutions for changing needs, converting scientific knowledge into added value, and improving production competencies. While the company supports its quality-focused production approach with international standards, it also continues its work in the fields of strategic raw materials and new production solutions.

Nuvita İlaç R&D Manager Akif Emre Kavak, stating that the research results reflect the company’s investments and project work in the field of R&D, made the following assessment:

“We see R&D as one of the fundamental elements of our sustainable growth and our goal of creating added value in production. Through the projects we develop by bringing together scientific accumulation with our production competence, we aim to contribute both to the development of our sector and to our country’s R&D ecosystem.”

Stating that they carry out innovative work at the Nuvita İlaç R&D center, Kavak noted that they are also developing their competencies in the field of strategic raw materials, in addition to new products and production solutions.

“In the upcoming period, we will continue to invest in science and innovation, and continue to develop innovative and high-value-added solutions that add value to human health.”

Nuvita İlaç’s latest performance in the Türkiye R&D 500 Research reveals that the company has recorded steady growth in its R&D investments and project capacity.

R&D expenditure: TRY 84.8 million

Increase in R&D expenditure: 53.8%

R&D expenditure ranking: from 248th to 231st place

Number of R&D projects: 49

Increase in number of projects: 28.9%

R&D project ranking: from 65th to 41st place

Nuvita İlaç aims to increase its R&D and innovation investments in the coming period, develop its production competencies, and produce high-value-added solutions for the healthcare sector.